Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Intellectus Partners LLC

Intellectus Partners LLC lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,204 shares of the biopharmaceutical company's stock after selling 4,200 shares during the period. Intellectus Partners LLC's holdings in Gilead Sciences were worth $1,255,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Brighton Jones LLC raised its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Trust Point Inc. raised its position in Gilead Sciences by 4.2% during the fourth quarter. Trust Point Inc. now owns 4,213 shares of the biopharmaceutical company's stock worth $389,000 after acquiring an additional 169 shares during the last quarter. Sargent Investment Group LLC acquired a new position in Gilead Sciences during the fourth quarter worth about $455,000. Stratos Investment Management LLC raised its position in Gilead Sciences by 6.2% during the fourth quarter. Stratos Investment Management LLC now owns 2,895 shares of the biopharmaceutical company's stock worth $267,000 after acquiring an additional 170 shares during the last quarter. Finally, Y.D. More Investments Ltd raised its position in Gilead Sciences by 43.3% during the fourth quarter. Y.D. More Investments Ltd now owns 1,602 shares of the biopharmaceutical company's stock worth $148,000 after acquiring an additional 484 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on GILD shares. Oppenheimer lowered their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Finally, DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Trading Up 1.3%

Shares of GILD stock opened at $110.46 on Friday. The stock has a market cap of $137.40 billion, a price-to-earnings ratio of 298.54, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $119.96. The firm's 50 day moving average price is $105.36 and its two-hundred day moving average price is $101.30.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences's revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.32) earnings per share. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.86%. Gilead Sciences's payout ratio is currently 66.53%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now directly owns 620,268 shares in the company, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,929 shares of company stock valued at $6,748,980. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.